The Effect and Safety of the Four Points Transversus Abdominis Plane Block

• ClinicalTrials.gov Identifier: NCT03598192
• Recruitment Status: Completed
• First Posted: July 26, 2018
• Last Update Posted: January 12, 2021
• Sponsor: Gia Dinh People Hospital
• Information provided by (Responsible Party): BINH HUYNH, Gia Dinh People Hospital

Study Description

Brief Summary:

The anterior abdominal wall from below the xiphoid to infraumbilical area is dominated by the sensory nerves which originate from the anterior rami of the thoracolumbar spinal nerves from T6-L1. The branches nerves from T7-T12 are between aponeurosis internal oblique and transversus abdominal muscle. They can be approached with the ultrasound guidance at subcostal and lateral abdominal wall position.

The bilateral transversus abdominis plane (TAP) block has been demonstrated effectiveness and safety in postoperative analgesia to the under abdominal surgery. However, the effect of one to the upper abdominal surgery is unclear.

The four points TAP block has been described the first in 2010. The effect of the four points TAP block in postoperative analgesia to the upper abdominal surgery has been reported in recent years. Besides, the effect of thoracic paravertebral block (PVB) in postoperative analgesia to liver resection was also reported. The both techniques have been performing in some studies. The effect and safety of the both techniques have been reported. However, the evidence level is still weak. The investigators need to find a technique, which has effectiveness as well as safety to replace the epidural analgesia, which was confirmed that had many complications, in postoperative analgesia to the hepatectomy.

The investigators hypothesized that the four points TAP block under the ultrasound guidance has more effectiveness than the thoracic paravertebral block in postoperative analgesia to the hepatectomy.

Condition or disease	Intervention/treatment	Phase
Liver Diseases; Adult Disease	Procedure: TAP; Procedure: PVB; Drug: Ropivacaine; Drug: Sufentanil	Not Applicable

Detailed Description:

This is a randomized, controlled, no blind, clinical trial. The study was approved by Board of Scientists and Ethic Council in Gia Dinh People Hospital on May 28, 2018. The written informed consent will be obtained from all subjects participating in the trial. The trial will be registered prior to patient enrollment at Gia Dinh People Hospital.

The investigators will select 60 participants who are selective hepatectomy with the "J-shape" incision, II-III of Anesthesiologists Society America (ASA), from 18-75 age. The cases have chronic pain, tolerance opioids, psychology disorder, and allergy opioids or ropivacaine will excluded. All of participants will be randomly divided two groups. There are TAP group and PVB group. Each one has 30 cases.

General anesthesia:

All of cases will be examined, prepared, supplied the study's information on the day before surgical date. The cases, who have enough selective standard, will be selected.

In the operating room, the participants will be performed general anesthesia The participants will be started anesthesia with 1 mg of midazolam, 0.3 mcg/kg of sufentanil, 1-1.5 mg/kg of propofol, and 0.6 mg/kg of rocuronium. Then, the participants will be maintained anesthesia with sevoflurane, sufentanil, and rocuronium. The end of surgery, they will be prevented postoperative nausea and vomiting with 4 mg of ondansetron; and reversed residual of muscle relaxant with sugammadex.

Approaching the transversus abdominal plane:

The technique will be performed at the end of surgery. The TAP group will be performed the four points TAP block under the ultrasound guidance with the ultrasound machine of Logiq E, and linear 12S probe. The participants will be performed TAP block at subcostal and lateral abdominal wall at right and left side with stimuplex needle (sized 18G, length 100 mm). The investigators will approach position between aponeurosis internal oblique and transversus abdominal muscle with in-plane real-time ultrasound technique. The investigators will inject 10 ml of ropivacaine 0.375% at each one. Then, the investigators will access one catheter at TAP at right side to continuously infuse ropivacaine 0.375% during 48 hours after surgery.

Approaching the thoracic paravertebral space:

The investigators will access one catheter into the right thoracic paravertebral space at T7 before beginning general anesthesia. At the end of surgery, we will inject 20 ml of ropivacaine 0.5% through catheter, and continuously infuse ropivacaine 0.25% during 48 hours after surgery.

Patients-controlled analgesia (PCA):

All of participants will be treated postoperative analgesia with sufentanil during 48 hours after operating. The sufentanil will be injected 2 mcg to patients before awaking. Then, the participants will be intravenously infused with PCA (2 mcg of single dosage, 6 minutes of lockout time, and 8 mcg/hour of limited dosage).

The both groups will be intravenously injected 0.2 mg/kg of ketamine at the pre-incisional and post-incisional. After operating, they will be taken 325 mg of paracetamol plus 37.5 mg of tramadol (ultracet tablet) every 8 hours.

Outcomes:

The primary outcome is the consumption of sufentanil (mcg) during 24 hours after operating. The secondary outcomes are the complications of technique, systemic toxicity of ropivacaine, side-effect of sufentanil, and satisfaction of participants.

The complications of the four points TAP block include hematoma in abdominal wall, and puncturing peritoneum. The complications of the thoracic paravertebral block include pneumothorax, and injecting vascular. The hematoma in abdominal wall, puncturing peritoneum, injecting vascular will be observed and recorded by one other anesthesiologist who has not attend the study. The pneumothorax will be diagnosed with the ultrasound by one doctor who is educated the general ultrasound. The systemic toxicity of ropivacaine include central nervous system (CNS) toxicity and cardiovascular toxicity. The signs and symptoms of CNS toxicity include tinnitus, disorientation, and ultimately, seizures. The signs and symptoms of cardiovascular toxicity include hypotension, dysrhythmias, and cardiac arrest. The complications will be treated depending on severity follow the protocol when they occured. The side-effect of sufentanil include sedation, dyspnea, pruritus, and nausea and vomiting. The sedation will be evaluated follow Ramsay scale. The dyspnea is decreasing oxygen saturation by pulse oximetry (SpO2) <= 92%, frequence <= 8 breaths/minute. The satisfaction will be measured follow visual analogue scale (VAS). The VAS scale has from 0 to 10, equivalent to the zero is complete dissatisfaction and the ten is highly satisfaction.

Data processing:

The investigators will process data with SPSS 25.0 (Reg No: 1975-01566-C). The consumption of sufentanil and satisfaction variables will be described by mean (SD) if it is standard distribution, or by median (CI 95%) if it isn't standard distribution. The variables of both groups will be compared by the independent T test or Mann-Whitney test. The quantitive variables will be described by frequency (percentage rate). The investigators will be compared by Chi-square test or exact's Fisher test. The sample size is calculated with 90% of power, and 20% of difference of the consumption of sufentanil of both groups, and 10% of cases losing. The alpha error is 0.05.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 30 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment

Intervention Model Description

The TAP group will be performed the four points TAP block under the ultrasound guidance with the ultrasound machine of Logiq E, and linear 12S probe. The participants will be performed TAP block at subcostal and lateral abdominal wall at right and left side with stimuplex needle (sized 18G, length 100 mm). The investigators will approach position between aponeurosis internal oblique and transversus abdominal muscle with in-plane real-time ultrasound technique. The investigators will inject 10 ml of ropivacaine 0.375% at each one. Then, the investigators will access one catheter at TAP at right side to continuously infuse ropivacaine 0.375% during 48 hours after surgery.

PVB group: the investigators will access one catheter into the right thoracic paravertebral space at T7 before beginning general anesthesia. At the end of surgery, the investigators will inject 20 ml of ropivacaine 0.5% through catheter, and continuously infuse ropivacaine 0.25% during 48 hours after surgery.

• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: The Effect and Safety of the Four Points Transversus Abdominis Plane Block Under the Ultrasound Guidance in Postoperative Analgesia to the Hepatectomy
• Actual Study Start Date: August 15, 2018
• Actual Primary Completion Date: September 1, 2018
• Actual Study Completion Date: July 30, 2020

Arms and Interventions

Arm	Intervention/treatment
Experimental: TAP group; The TAP block is performed under the ultrasound guidance at four points: at subcostal and lateral abdominal wall at right-side and left-side. Drug: ropivacaine 0.375% 40 ml (maximum dose <= 3 mg/kg). Maintenance: ropivacaine 0.375% 8 ml/hour during 48 hours.	Procedure: TAP; The TAP group will be performed at four points at abdominis plane with ropivacaine 0.375%; Other Name: The four points TAP block; Drug: Ropivacaine; Ropivacaine has been treated the both group; Other Name: have not been specified; Drug: Sufentanil; Sufentanil has been included in Arm/Group Descriptions; Other Name: Sufentanil PCA
Experimental: PVB group; The paravertebral block is performed under the ultrasound guidance at T7. Drug: ropivacaine 0.5% 20 ml (maximum dose <= 3 mg/kg). Maintenance: ropivacaine 0.25% 8 ml/hour during 48 hours.	Procedure: PVB; The PVB group will be performed at paravertebral space T7 with ropivacaine 0.5%; Other Name: The paravertebral block; Drug: Ropivacaine; Ropivacaine has been treated the both group; Other Name: have not been specified; Drug: Sufentanil; Sufentanil has been included in Arm/Group Descriptions; Other Name: Sufentanil PCA

Outcome Measures

Primary Outcome Measures :

1. The consumption of sulfentanil (mean) [ Time Frame: 24 hours ]
   The consumption of sufentanil is total dose of sufentanil which the participant used during 24 hours. Sufentanil is intravenously infused with PCA, with single dose 1 mcg, limit dose 8 mcg per a hour, and lockout time 5 minutes.

Secondary Outcome Measures :

1. The complications of technique (frequency) [ Time Frame: 24 hours ]
   included injected vascular, hematoma abdominal, pneumothorax, punctured peritoneum, systemic toxicity of ropivacaine
2. Side-effect of sulfentanil (frequency) [ Time Frame: 48 hours ]
   include sedation, pruritus, nausea and vomiting, dyspnea
3. Satisfaction (mean) [ Time Frame: 24 hours ]
   evaluated with Visual analogue scale (VAS). VAS is from 0 to 10 that means the minimum satisfaction is 0 score and the maximum satisfaction is 10 scores.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 75 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Subjects has selective hepatectomy
• Subjects has had II-III of Anesthesiologists Society Americans

Exclusion Criteria:

• History of chronic pain
• History of tolerance opioids
• History of psychology disorder
• Allergic to ropivacaine or opioids

Contacts and Locations

Locations

Vietnam

Binh Huynh

Ho Chi Minh City, Ho Chi Minh, Vietnam, 70000

Sponsors and Collaborators

Gia Dinh People Hospital

Investigators

• Study Chair: Binh V Huynh, Mr; Nhan dan Gia Dinh Hospital

More Information

• Responsible Party: BINH HUYNH, Department of Anesthesiology, Gia Dinh People Hospital
• ClinicalTrials.gov Identifier: NCT03598192
• Other Study ID Numbers: 15-2018/CN-HĐĐĐ
• First Posted: July 26, 2018
• Last Update Posted: January 12, 2021
• Last Verified: January 2021

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No

Keywords provided by BINH HUYNH, Gia Dinh People Hospital:

Hepatectomy; Transversus abdominis plane block (TAP block); Paravertebral block; Postoperative analgesia; Liver resection

Additional relevant MeSH terms:

Liver Diseases; Digestive System Diseases; Sufentanil; Dsuvia; Ropivacaine; Anesthetics, Local; Anesthetics; Central Nervous System Depressants; Physiological Effects of Drugs; Sensory System Agents; Peripheral Nervous System Agents; Analgesics, Opioid; Narcotics; Analgesics; Adjuvants, Anesthesia; Anesthetics, Intravenous; Anesthetics, General